<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>LA072789-0137</title>
	</head>
	<body>
		<main>
			<p><P> July 27, 1989, Thursday, Orange County Edition  </P> <P> SHAREHOLDERS OK SMITHKLINE DEAL SPINNING OFF BECKMAN, ALLERGAN  </P> <P> The newly merged company, SmithKline Beecham, is a prescription and  over-the-counter drug company with more than $6.7 billion in annual revenues,  second only to Merck &amp; Co. Its headquarters will be in London with Beecham  chief executive Robert Bauman retaining that title and SmithKline chief  executive Henry Wendt shifting to chairman.  </P> <P> As part of the merger, Irvine-based Allergan Inc. and Fullerton-based Beckman  Instruments Inc., which had been acquired by SmithKline several years ago, were  spun off as separately traded public companies, severing all ties with the  pharmaceutical giant.  </P> <P> SmithKline Beckman took a small step toward divestiture of its Orange County  subsidiaries last November when it took 16% of Beckman Instruments public.  </P> <P> On Wednesday, Allergan, a maker of eye- and skin-care products, and Beckman  Instruments, a medical instruments company, immediately joined the roster of  Orange County's five largest public corporations, according to Newport  Securities. In 1988, Allergan had earnings of $80 million on revenue of $756  million, while Beckman Instruments had earnings of $42.5 million on revenue of  $770 million.  </P> <P> As part of the merger agreement, all of the Beckman and Allergan stock will be  issued to former SmithKline Beckman shareholders.  </P> <P> About 66.7 million shares of Allergan stock will begin trading today on the New  York Stock Exchange. In pre-sale agreements with brokers Wednesday, the stock  was selling for $24.50 a share, according to Allergan spokesperson Jamie  Trevor.  </P> <P> Today 28.5 million shares of Beckman stock also will become tradable on the New  York Stock Exchange. Wednesday's spinoff apparently had little influence on  Beckman investors. At the close of the market, the company's stock was selling  in light trading for $18.38 a share, up 25 cents.  </P> <P> Allergan and Beckman executives said Wednesday that although they believe that  both companies fared well under SmithKline's leadership, they expect that the  renewed independence will give added incentive to their employees and  management.  </P> <P> Industry analysts observed that the strong earnings of both companies no longer  will be hidden by the overall performance of the much-larger SmithKline Beckman  corporation.  </P> <P> Management and other employees of Allergan and Beckman are expected to take  advantage of opportunities to purchase stock in the new companies by exercising  stock options and participating in newly established employee stock ownership  plans.  </P> <P> "It is an exciting time for us. A time of recommitment and rebirth," said Gavin  Herbert, Allergan's chairman and chief executive officer.  </P> <P> George Kilmain, Beckman's vice president of finance, said, "It is good for  employees to identify with Beckman as an entity. They are making the products  and now they can see how we are doing. You tend to lose your identify as part  of a larger corporation."  </P> <P> Allergan was founded in 1948 by Gavin Herbert Sr. in a shop above his Los  Angeles drugstore. It was bought by SmithKline for $259 million in 1980.  </P> <P> Beckman Instruments was started in a Pasadena garage in 1935 by Arnold O.  Beckman. It was purchased by SmithKline in 1982 for $1 billion.  </P> <P> SmithKline decided to divest Beckman and Allergan because their business focus  was considered peripheral for a pharmaceutical house and because SmithKline and  Beecham wanted to merge as equal partners, said SmithKline spokesman Alan  Wachter. For the same reasons, he said, Beecham spun off a cosmetics business.  </P> <P> In recent weeks Beckman and Allergan executives have been on the road touting  their companies to securities analysts, many of whom had lost touch with the  companies when they merged into SmithKline Beckman.  </P> <P> Both Beckman and Allergan are considered financially strong by industry  analysts, particularly Allergan because of that company's continued rapid  growth and leadership position in a burgeoning industry.  </P> <P> David MacCallum, managing director of Hambrecht &amp; Quist Inc. in New York,  said Allergan is "one of a handful of unique pharmaceutical companies that  identified a niche and developed a dominant position within that niche. I think  Allergan will continue to grow at a rate significantly faster than the rest of  the pharmaceutical industry."  </P> <P> John Osgood, a medical analyst for Alex Brown &amp; Sons in Boston, said he  believes that at Beckman "independence can serve as a bit of revitalization. I  think it is an attitude more than anything else."  </P> <P> He noted that one of Beckman's major markets, medical research, currently is  lagging because of cutbacks in government spending. But he said he expects the  company's stock to perform well "in the long term."  </P> <P> THE COMPANIES AT A GLANCE  </P> <TABLE CWL="3.21IN:4.09IN:2.99IN" WDM="ABS" NCOLS="3"> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> BECKMAN  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> INSTRUMENTS  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> ALLERGAN  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL> </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> Headquarters  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> Fullerton  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> Irvine  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> 1988 revenue  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> $770 million  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> $756 million  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> 1989 first-quarter  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> revenue  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> $199 million  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> $178.6 million  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> 1989 second-quarter  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> revenue  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> $200 million  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> n/a  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> 1988 earnings  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> $42.5 million  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> $80 million  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> 1989 first-quarter  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> earnings  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> $10.7 million  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> $17.3 million  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> 1989 second-quarter  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> earnings  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> $11.4 million  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> n/a  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> Primary Products  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> Analytical and  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> Eye-care and  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> industrial instruments,  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> skin-care  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> control systems,  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> products  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> electronic components  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> Year of acquisition  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> 1982  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> 1980  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> by SmithKline  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> Employees  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> 7,300 worldwide  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> 6,000 worldwide  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> 2,300 in Fullerton and Brea  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> 2,200 in Irvine  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> Wednesday's closing  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> 18.35 up .25  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> n/a  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> stock price  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> <TABLEROW> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> Chief executive  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="C" CVJ="C"> Louis T. Rosso  </TABLECELL> <CELLRULE>  </CELLRULE> <TABLECELL CHJ="L" CVJ="C"> Gavin Herbert Jr.  </TABLECELL> <CELLRULE>  </CELLRULE> </TABLEROW> <ROWRULE>  </ROWRULE> </TABLE></p>
		</main>
</body></html>
            